Palifermin

From Wikipedia, the free encyclopedia

Palifermin
Systematic (IUPAC) name
?
Identifiers
CAS number	162394-19-6
ATC code	V03AF08
PubChem	?
DrugBank	BTD00042
Chemical data
Formula	C₇₂₁H₁₁₄₂N₂₀₂O₂₀₄S₉
Mol. mass	16192.7 g/mol
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	?

Palifermin (Kepivance, Amgen) is a human recombinant keratinocyte growth factor (KGF) produced in Escherichia coli. When patients with blood cancers undergo high dose chemotherapy and radiation to undergo bone marrow transplant, they usually get severe oral mucositis. Palifermin binds to epithelial cell-surface receptors and stimulates epithelial cell proliferation, differentiation, and upregulation of cytoprotective mechanisms. It reduces the incidence and duration of severe oral mucitis by protecting those cells and stimulating the growth of new epithelial cells to build up the mucosal barrier.

Palifermin costs 5,000 Euros per treatment for a 70 kg patient ^[1]

[edit] References

^ NEW DRUGS in TRANSPLANTATION, EBMT Meeting, France, March 2007 C. PAILLET, Pharmacist, Pharm D. C. RENZULLO, Pharmacist, Pharm D. Edouard Herriot Hospital, Lyon, FRANCE

Spielberger R, Stiff P, Bensinger W, et al., Palifermin for oral mucositis after intensive therapy for hematologic cancers, N Engl J Med 2004;351:2590-8.

Garfunkel AA, Oral mucositis -- the search for a solution. N Engl J Med 2004;351:2649-51.

Rosen LS, Abdi E, Davis ID, et al., Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy, J Clin Oncol 2006;24:5194-5200.